Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science…
Pharmaceuticals, Biotechnology and Life Sciences
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science…
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk…
—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4)…
– As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was…
— Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo — — Subgroup…
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of…
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct…
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated…
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on…
– Promising preclinical data showcasing Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead…